Dec 11 (Reuters) -
- ARCH BIOPARTNERS FORMS NEW SUBSIDIARY TO PURSUE A PHASE I TRIAL IN AUSTRALIA FOR METABLOK (LSALT PEPTIDE)
- ARCH BIOPARTNERS INC - STARTED HUMAN TRIAL APPLICATION PROCESS WITH ALFRED HEALTH HUMAN RESEARCH ETHICS COMMITTEE
- ARCH BIOPARTNERS - FORMED ARCH CLINICAL PTY LTD, A UNIT IN AUSTRALIA, TO PURSUE A PHASE I TRIAL IN AUSTRALIA FOR METABLOK (LSALT PEPTIDE)
- ARCH BIOPARTNERS - DRAFT APPLICATION ACCEPTED FOR REGISTRATION ON DEC 10, 2018 & TO BE FOLLOWED BY FULL SUBMISSION & REVIEW IN EARLY JANUARY 2019
- ARCH BIOPARTNERS INC - DECISION REGARDING TRIAL APPROVAL IS EXPECTED BEFORE FEBRUARY 2019
